

Amendments to the Claims:

This listing of Claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. to 113. (Cancelled)

114. (Previously Presented) A d-form retro-inverted peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 (ZElan144), SEQ ID NO:2 (ZElan145), and SEQ ID NO:3 (ZElan146) wherein said peptide binds to a domain of a gastro-intestinal tract transport receptor selected from the group consisting of amino acids 29-273 of human intestinal oligopeptide transporter (HPT1), amino acids 391-571 of human oligopeptide transporter (hPEPT1), amino acids 387-685 of human D2 clone (D2H), and amino acids 272-667 of human sucrase isomaltase (hSI), wherein said peptide is no more than 50 amino acid residues.

115. to 117. (Cancelled)

118. (Previously Presented) The peptide of claim 114, wherein the peptide is no more than 40 amino acid residues.

119. (Previously Presented) The peptide of claim 114, wherein the peptide is no more than 30 amino acid residues.

120. (Previously Presented) The peptide of claim 114, wherein the peptide is no more than 20 amino acid residues.

121 to 131. (Cancelled)

132. (Previously Presented) A pharmaceutical composition comprising a

therapeutically effective amount of a composition comprising the peptide of claim 114 and a pharmaceutically acceptable carrier.

133. (Previously Presented) A composition comprising the peptide of claim 114, wherein the peptide is coated onto the surface of a nanoparticle or microparticle, absorbed onto the surface of a nanoparticle or microparticle, or covalently bonded to the surface of a nanoparticle or microparticle.

134. (Previously Presented) A nanoparticle or microparticle formed from the peptide of claim 114.

135. to 144. (Cancelled)